ArticleFrontiers in pharmacology2020

Pristimerin Suppresses RANKL-Induced Osteoclastogenesis and Ameliorates Ovariectomy-Induced Bone Loss.

Dahu Qi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.